Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS) from its SEC filings: 2025 revenue $291.8 million (+44% vs the year before), net margin 0%, free cash flow $28.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $291.8 million |
| Revenue growth | +44% |
| Net income | $554,000 |
| Net margin | 0.2% |
| Free cash flow | $28.6 million |
| Diluted EPS | $0.00 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +29% |
| Cash | $121.7 million |
| Long-term debt | $188.8 million |
| Share count, 1 year | +13% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.